5—FU治疗药物监测现状及其与结直肠癌化疗毒性相关性的研究进展(4)
[ 6 ] KALDATE RR，HAREGEWOIN A，GRIER CE，et al. Modeling the 5-fluorouracil area under the curve versus dose relationship to develop a pharmacokinetic dosing algorithm for colorectal cancer patients receiving FOLFOX6[J]. Oncologist，2012，17(3)： 296-302.
[ 7 ] SAIF MW，CHOMA A，SALAMONE SJ，et al. Pharmacokinetically guided dose adjustment of 5-fluorouracil： a rational approach to improving therapeutic outcomes[J]. J Natl Cancer Inst，2009，101(22)：1543-1552.
, http://www.100md.com
[ 8 ] V?ZQUEZ C，ORLOVA M，ANGRIMAN F，et al. Prediction of severe toxicity in adult patients under treatment with 5-fluorouracil： a prospective cohort study[J]. Anticancer Drugs，2017，28(9)： 1039-1046.
[ 9 ] GOEL G，SEHGAL R，MEISNER DJ，et al. Therapeutic drug monitoring of 5-fluorouracil (5-FU) in the treatment of patients with colorectal cancer (CRC)[J]. J Clin Oncol，2015. DOI： 10.1200/jco.2015.33.3
[10] LEE JJ，BEUMER JH，CHU E. Therapeutic drug monitoring of 5-fluorouracil[J]. Cancer Chemother Pharmacol，2016，78(3)：447-464.
, http://www.100md.com
[11] 張红雨，赵春临，叶延伟. 氟尿嘧啶血药浓度监测对于结直肠癌病人化疗疗效的研究进展[J]. 河南医学研究，2016，25(2)：260-262.
[12] 柳芳，陈文倩，李朋梅，等. 治疗药物监测的概念探析[J].实用药物与临床，2016，19(3)：380-383.
[13] 时静，陈海生，段存贤，等. 5-氟尿嘧啶治疗药物监测的研究现状[J]. 中国临床药理学杂志，2016，32(11)：1053-1056.
[14] 吴丽敏，王鸿梅，李军. 氟尿嘧啶药理学及其相关代谢酶的遗传药理学进展[J].浙江临床医学，2014，16(3)：481-483.
[15] HANSEN RM，RYAN L，ANDERSON T，et al. Phase Ⅲ study of bolus versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer[J]. J Nat Cancer Inst，1996，88(10)：668-674.
, http://www.100md.com
[16] DE GRAMONT A，BOSSET JF，MILAN C，et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and flurouracin bolus plus continuous infusion for advanced colorectal cancer： a French intergroup study[J]. J Clin Oncol，1997，15(2)：808-815.
[17] GAMELIN E，DELVA R，JACOB J ，et al. Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage： results of a multicenter randomized trial of patients with metastatic colorectal cancer[J]. J Clin Oncol，2008，26(13)： 2099- 2105.
, http://www.100md.com
[18] KIRKWOOD JM，ENSMINGER W，ROSOWSKY A，et al. Comparison of pharmacokinetics of 5-fluorouracil and 5-fluorouracil with concurrent thymidine infusions in a PhaseⅠtrial[J]. Cancer Res，1980，40(1)：107-113.
[19] PATEL JN，DEAL AM，MCLEOD H，et al. Evaluating variability in fluorouracil (FU) exposure in obese and non-obese patients with colorectal cancer using full weight- based dosing[J]. J Clin Oncol，2013. DOI：10.1200/jco.2013. 31.4, 百拇医药(张娟 吴东媛 刘铎 董梅)
[ 7 ] SAIF MW，CHOMA A，SALAMONE SJ，et al. Pharmacokinetically guided dose adjustment of 5-fluorouracil： a rational approach to improving therapeutic outcomes[J]. J Natl Cancer Inst，2009，101(22)：1543-1552.
, http://www.100md.com
[ 8 ] V?ZQUEZ C，ORLOVA M，ANGRIMAN F，et al. Prediction of severe toxicity in adult patients under treatment with 5-fluorouracil： a prospective cohort study[J]. Anticancer Drugs，2017，28(9)： 1039-1046.
[ 9 ] GOEL G，SEHGAL R，MEISNER DJ，et al. Therapeutic drug monitoring of 5-fluorouracil (5-FU) in the treatment of patients with colorectal cancer (CRC)[J]. J Clin Oncol，2015. DOI： 10.1200/jco.2015.33.3
[10] LEE JJ，BEUMER JH，CHU E. Therapeutic drug monitoring of 5-fluorouracil[J]. Cancer Chemother Pharmacol，2016，78(3)：447-464.
, http://www.100md.com
[11] 張红雨，赵春临，叶延伟. 氟尿嘧啶血药浓度监测对于结直肠癌病人化疗疗效的研究进展[J]. 河南医学研究，2016，25(2)：260-262.
[12] 柳芳，陈文倩，李朋梅，等. 治疗药物监测的概念探析[J].实用药物与临床，2016，19(3)：380-383.
[13] 时静，陈海生，段存贤，等. 5-氟尿嘧啶治疗药物监测的研究现状[J]. 中国临床药理学杂志，2016，32(11)：1053-1056.
[14] 吴丽敏，王鸿梅，李军. 氟尿嘧啶药理学及其相关代谢酶的遗传药理学进展[J].浙江临床医学，2014，16(3)：481-483.
[15] HANSEN RM，RYAN L，ANDERSON T，et al. Phase Ⅲ study of bolus versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer[J]. J Nat Cancer Inst，1996，88(10)：668-674.
, http://www.100md.com
[16] DE GRAMONT A，BOSSET JF，MILAN C，et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and flurouracin bolus plus continuous infusion for advanced colorectal cancer： a French intergroup study[J]. J Clin Oncol，1997，15(2)：808-815.
[17] GAMELIN E，DELVA R，JACOB J ，et al. Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage： results of a multicenter randomized trial of patients with metastatic colorectal cancer[J]. J Clin Oncol，2008，26(13)： 2099- 2105.
, http://www.100md.com
[18] KIRKWOOD JM，ENSMINGER W，ROSOWSKY A，et al. Comparison of pharmacokinetics of 5-fluorouracil and 5-fluorouracil with concurrent thymidine infusions in a PhaseⅠtrial[J]. Cancer Res，1980，40(1)：107-113.
[19] PATEL JN，DEAL AM，MCLEOD H，et al. Evaluating variability in fluorouracil (FU) exposure in obese and non-obese patients with colorectal cancer using full weight- based dosing[J]. J Clin Oncol，2013. DOI：10.1200/jco.2013. 31.4